1.Pitfalls in Using Electrophysiological Studies to Diagnose Neuromuscular Disorders.
Yong Seo KOO ; Charles S CHO ; Byung Jo KIM
Journal of Clinical Neurology 2012;8(1):1-14
Electrodiagnostic testing is used widely for the full characterization of neuromuscular disorders and for providing unique information on the processes underlying the pathology of peripheral nerves and muscles. However, such testing should be considered as an extension of anamnesis and physical examination, not as pathognomonic of a specific disease entity. There are many pitfalls that could lead to erroneous interpretation of electrophysiological study results when the studies are not performed properly or if they are performed in the presence of anatomical aberrations. The diagnostic reliability of electrodiagnostic studies can be improved and the associated pitfalls overcome if the physician is familiar with all of those possible pitfalls. In this article we discuss the most common and important pitfalls associated with electrodiagnostic medicine.
Electromyography
;
Muscles
;
Peripheral Nerves
;
Physical Examination
2.Validation of a Korean Version of the Insomnia Severity Index.
Yong Won CHO ; Mei Ling SONG ; Charles M MORIN
Journal of Clinical Neurology 2014;10(3):210-215
BACKGROUND AND PURPOSE: The purposes of this study were to standardize and validate a Korean version of the Insomnia Severity Index (ISI-K), and to evaluate its clinical usefulness. METHODS: We translated the ISI into Korean and then translated it back into English to check its accuracy. The 614 patients with sleep disorders who were enrolled in this study comprised 169 with primary insomnia, 133 with comorbid insomnia, and 312 with obstructive sleep apnea. All subjects underwent one night of polysomnography (PSG) and completed the Korean versions of both the Pittsburgh Sleep Quality Index (PSQI-K) and the Epworth Sleepiness Scale, as well as the ISI-K. The ISI-K was compared to these sleep scales and various PSG sleep parameters. RESULTS: The internal consistency the ISI-K total score was confirmed by a Cronbach's alpha of 0.92, and the item-to-total-score correlations (item-total correlations) ranged from 0.65 to 0.84, suggesting adequate reliability. The correlation between the ISI-K total score and PSQI-K was 0.84, which suggested adequate convergent validity. Low-to-moderate correlations were obtained between the ISI-K total score and PSG-defined sleep parameters: 0.22 for sleep onset latency, 0.38 for wake after sleep onset, and 0.46 for sleep efficiency. A cutoff score of 15.5 on the ISI-K was optimal for discriminating patients with insomnia. The test-retest scores over a 4-week interval with 34 subjects yielded a correlation coefficient of 0.86, suggesting excellent temporal stability. CONCLUSIONS: The findings of this study show that the ISI-K is a reliable and valid instrument for assessing the severity of insomnia in a Korean population.
Humans
;
Polysomnography
;
Sleep Apnea, Obstructive
;
Sleep Wake Disorders
;
Sleep Initiation and Maintenance Disorders*
;
Weights and Measures
3.Antigen Nonspecific Death of Immature Thymocytes by Corticosteroids and TNF.
Keunhee OH ; Charles D SURH ; Jaejin CHO ; Dong Sup LEE
Immune Network 2004;4(2):81-87
BACKGROUND: In the thymus, developing thymocytes continually interact with thymic epithelial cell components. Self MHC restriction of mature T cells are imposed in the thymus through interaction of immature double positive thymocytes and thymic cortical epithelial cells. The site of negative selection, however, is a matter of debate. Through systemic injection of anti-TCR antibody or antigenic peptides, investigators suggested that most of the negative selection occurs in the thymic cortex. But the requirements for negative selection, i.e cellular counterparts and costimulatory molecules are more available in the medulla or cortico-medullary junction rather than in the thymic cortex. METHODS: The direct and indirect pathways of thymocyte death after systemic anti-TCR antibody injection were separated through several experimental systems. B6 mice were either adrenalectomized or sham-adrenalectomized to evaluate the role of endogenous glucocorticoids from adrenal gland. Role of TNF were evaluated through using TNF receptor double knockout mice. RESULTS: We found that without indirectly acting mediators such as TNF-alpha or corticosteroid, double positive thymocyte death were minimal by systemic injection of anti-TCR antibody in TNF receptor double knockout neonatal mice. Also by analyzing neonatal wild-type mice with adoptively transferred mature T cells, only peripheral activation of mature T cells could induce extensive double positive thymocyte death. CONCLUSION: Thus, systemically injected anti-TCR antibody mediated thymocyte death are mostly induced through indirect pathway.
Adrenal Cortex Hormones*
;
Adrenal Glands
;
Animals
;
Epithelial Cells
;
Glucocorticoids
;
Humans
;
Mice
;
Mice, Knockout
;
Peptides
;
Receptors, Tumor Necrosis Factor
;
Research Personnel
;
T-Lymphocytes
;
Thymocytes*
;
Thymus Gland
;
Tumor Necrosis Factor-alpha
5.Deep Brain Stimulation: Technology at the Cutting Edge.
Rahul S SHAH ; Su Youne CHANG ; Hoon Ki MIN ; Zang Hee CHO ; Charles D BLAHA ; Kendall H LEE
Journal of Clinical Neurology 2010;6(4):167-182
Deep brain stimulation (DBS) surgery has been performed in over 75,000 people worldwide, and has been shown to be an effective treatment for Parkinson's disease, tremor, dystonia, epilepsy, depression, Tourette's syndrome, and obsessive compulsive disorder. We review current and emerging evidence for the role of DBS in the management of a range of neurological and psychiatric conditions, and discuss the technical and practical aspects of performing DBS surgery. In the future, evolution of DBS technology may depend on several key areas, including better scientific understanding of its underlying mechanism of action, advances in high-spatial resolution imaging and development of novel electrophysiological and neurotransmitter microsensor systems. Such developments could form the basis of an intelligent closed-loop DBS system with feedback-guided neuromodulation to optimize both electrode placement and therapeutic efficacy.
Brain
;
Deep Brain Stimulation
;
Depression
;
Dystonia
;
Electrodes
;
Epilepsy
;
Neurotransmitter Agents
;
Obsessive-Compulsive Disorder
;
Parkinson Disease
;
Tourette Syndrome
;
Tremor
6.Deep Brain Stimulation: Technology at the Cutting Edge.
Rahul S SHAH ; Su Youne CHANG ; Hoon Ki MIN ; Zang Hee CHO ; Charles D BLAHA ; Kendall H LEE
Journal of Clinical Neurology 2010;6(4):167-182
Deep brain stimulation (DBS) surgery has been performed in over 75,000 people worldwide, and has been shown to be an effective treatment for Parkinson's disease, tremor, dystonia, epilepsy, depression, Tourette's syndrome, and obsessive compulsive disorder. We review current and emerging evidence for the role of DBS in the management of a range of neurological and psychiatric conditions, and discuss the technical and practical aspects of performing DBS surgery. In the future, evolution of DBS technology may depend on several key areas, including better scientific understanding of its underlying mechanism of action, advances in high-spatial resolution imaging and development of novel electrophysiological and neurotransmitter microsensor systems. Such developments could form the basis of an intelligent closed-loop DBS system with feedback-guided neuromodulation to optimize both electrode placement and therapeutic efficacy.
Brain
;
Deep Brain Stimulation
;
Depression
;
Dystonia
;
Electrodes
;
Epilepsy
;
Neurotransmitter Agents
;
Obsessive-Compulsive Disorder
;
Parkinson Disease
;
Tourette Syndrome
;
Tremor
7.Intraoperative Neurophysiological Monitoring : A Review of Techniques Used for Brain Tumor Surgery in Children
Keewon KIM ; Charles CHO ; Moon suk BANG ; Hyung ik SHIN ; Ji Hoon PHI ; Seung Ki KIM
Journal of Korean Neurosurgical Society 2018;61(3):363-375
Intraoperative monitoring (IOM) utilizes electrophysiological techniques as a surrogate test and evaluation of nervous function while a patient is under general anesthesia. They are increasingly used for procedures, both surgical and endovascular, to avoid injury during an operation, examine neurological tissue to guide the surgery, or to test electrophysiological function to allow for more complete resection or corrections. The application of IOM during pediatric brain tumor resections encompasses a unique set of technical issues. First, obtaining stable and reliable responses in children of different ages requires detailed understanding of normal ageadjusted brain-spine development. Neurophysiology, anatomy, and anthropometry of children are different from those of adults. Second, monitoring of the brain may include risk to eloquent functions and cranial nerve functions that are difficult with the usual neurophysiological techniques. Third, interpretation of signal change requires unique sets of normative values specific for children of that age. Fourth, tumor resection involves multiple considerations including defining tumor type, size, location, pathophysiology that might require maximal removal of lesion or minimal intervention. IOM techniques can be divided into monitoring and mapping. Mapping involves identification of specific neural structures to avoid or minimize injury. Monitoring is continuous acquisition of neural signals to determine the integrity of the full longitudinal path of the neural system of interest. Motor evoked potentials and somatosensory evoked potentials are representative methodologies for monitoring. Free-running electromyography is also used to monitor irritation or damage to the motor nerves in the lower motor neuron level : cranial nerves, roots, and peripheral nerves. For the surgery of infratentorial tumors, in addition to free-running electromyography of the bulbar muscles, brainstem auditory evoked potentials or corticobulbar motor evoked potentials could be combined to prevent injury of the cranial nerves or nucleus. IOM for cerebral tumors can adopt direct cortical stimulation or direct subcortical stimulation to map the corticospinal pathways in the vicinity of lesion. IOM is a diagnostic as well as interventional tool for neurosurgery. To prove clinical evidence of it is not simple. Randomized controlled prospective studies may not be possible due to ethical reasons. However, prospective longitudinal studies confirming prognostic value of IOM are available. Furthermore, oncological outcome has also been shown to be superior in some brain tumors, with IOM. New methodologies of IOM are being developed and clinically applied. This review establishes a composite view of techniques used today, noting differences between adult and pediatric monitoring.
Adult
;
Anesthesia, General
;
Anthropometry
;
Brain Neoplasms
;
Brain
;
Child
;
Cranial Nerves
;
Electromyography
;
Evoked Potentials, Auditory, Brain Stem
;
Evoked Potentials, Motor
;
Evoked Potentials, Somatosensory
;
Humans
;
Infratentorial Neoplasms
;
Intraoperative Neurophysiological Monitoring
;
Longitudinal Studies
;
Monitoring, Intraoperative
;
Motor Neurons
;
Muscles
;
Neurophysiology
;
Neurosurgery
;
Peripheral Nerves
;
Prospective Studies
8.Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy.
Charles J CHO ; Ho June SONG ; Gin Hyug LEE ; Kee Don CHOI ; Yong Hee KIM ; Jin Sook RYU ; Sung Bae KIM ; Jong Hoon KIM ; Seung Il PARK ; Hwoon Yong JUNG
The Korean Journal of Internal Medicine 2017;32(3):443-451
BACKGROUND/AIMS: Approximately 30% of esophageal cancer (EC) patients cannot complete endoscopic ultrasonography (EUS) due to malignant stricture (EUS non-traversability). This study examines clinical implications of EUS non-traversability in patients with advanced locoregional squamous EC receiving preoperative chemoradiotherapy (CRT) followed by esophagectomy. METHODS: We retrieved data on 89 consecutive patients with advanced locoregional squamous EC (stage II or III). Relevant clinical and tumor-specific parameters were reviewed retrospectively. Significant factors affecting survival was determined by Cox regression analysis. RESULTS: EUS non-traversable EC was observed in 26 of 89 patients (29.2%). Median serum albumin level (3.6 g/dL vs. 3.9 g/dL, p = 0.028), tumor length (6.0 cm vs. 4.0 cm, p = 0.002), and percentage of clinical stage III disease (65.4% vs. 38.1%, p = 0.019) were significantly different between the patients with EUS non-traversable and traversable EC, respectively. Patients with EUS non-traversable EC demonstrated a significantly lower 5-year overall survival than patients with EUS traversable EC (30.8% vs. 49.3%, p = 0.023). In multivariate analysis, weight loss ≥ 10% (p = 0.033), EUS non-traversability (p = 0.003), non-response to preoperative CRT (p = 0.002), and incompletion of esophagectomy (p = 0.002) were significant negative factors of survival. CONCLUSIONS: EUS non-traversability has significant negative prognostic implications in patients with advanced locoregional squamous EC receiving preoperative CRT followed by esophagectomy.
Carcinoma, Squamous Cell
;
Chemoradiotherapy
;
Constriction, Pathologic
;
Endosonography*
;
Esophageal Neoplasms*
;
Esophagectomy
;
Humans
;
Multivariate Analysis
;
Prognosis
;
Retrospective Studies
;
Serum Albumin
;
Weight Loss
9.Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy.
Charles J CHO ; Ho June SONG ; Gin Hyug LEE ; Kee Don CHOI ; Yong Hee KIM ; Jin Sook RYU ; Sung Bae KIM ; Jong Hoon KIM ; Seung Il PARK ; Hwoon Yong JUNG
The Korean Journal of Internal Medicine 2017;32(3):443-451
BACKGROUND/AIMS: Approximately 30% of esophageal cancer (EC) patients cannot complete endoscopic ultrasonography (EUS) due to malignant stricture (EUS non-traversability). This study examines clinical implications of EUS non-traversability in patients with advanced locoregional squamous EC receiving preoperative chemoradiotherapy (CRT) followed by esophagectomy. METHODS: We retrieved data on 89 consecutive patients with advanced locoregional squamous EC (stage II or III). Relevant clinical and tumor-specific parameters were reviewed retrospectively. Significant factors affecting survival was determined by Cox regression analysis. RESULTS: EUS non-traversable EC was observed in 26 of 89 patients (29.2%). Median serum albumin level (3.6 g/dL vs. 3.9 g/dL, p = 0.028), tumor length (6.0 cm vs. 4.0 cm, p = 0.002), and percentage of clinical stage III disease (65.4% vs. 38.1%, p = 0.019) were significantly different between the patients with EUS non-traversable and traversable EC, respectively. Patients with EUS non-traversable EC demonstrated a significantly lower 5-year overall survival than patients with EUS traversable EC (30.8% vs. 49.3%, p = 0.023). In multivariate analysis, weight loss ≥ 10% (p = 0.033), EUS non-traversability (p = 0.003), non-response to preoperative CRT (p = 0.002), and incompletion of esophagectomy (p = 0.002) were significant negative factors of survival. CONCLUSIONS: EUS non-traversability has significant negative prognostic implications in patients with advanced locoregional squamous EC receiving preoperative CRT followed by esophagectomy.
Carcinoma, Squamous Cell
;
Chemoradiotherapy
;
Constriction, Pathologic
;
Endosonography*
;
Esophageal Neoplasms*
;
Esophagectomy
;
Humans
;
Multivariate Analysis
;
Prognosis
;
Retrospective Studies
;
Serum Albumin
;
Weight Loss
10.Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.
Charles S FUCHS ; Kei MURO ; Jiri TOMASEK ; Eric VAN CUTSEM ; Jae Yong CHO ; Sang Cheul OH ; Howard SAFRAN ; György BODOKY ; Ian CHAU ; Yasuhiro SHIMADA ; Salah Eddin AL-BATRAN ; Rodolfo PASSALACQUA ; Atsushi OHTSU ; Michael EMIG ; David FERRY ; Kumari CHANDRAWANSA ; Yanzhi HSU ; Andreas SASHEGYI ; Astra M LIEPA ; Hansjochen WILKE
Journal of Gastric Cancer 2017;17(2):132-144
PURPOSE: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. MATERIALS AND METHODS: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline clinical and laboratory factors common in both studies were examined. Model building started with covariate screening using univariate Cox models (significance level=0.05). A stepwise multivariable Cox model identified the final prognostic factors (entry+exit significance level=0.01). Cox models were stratified by treatment and geographic region. The process was repeated to identify baseline prognostic quality of life (QoL) parameters. RESULTS: Of 1,020 randomized patients, 953 (93%) patients without any missing covariates were included in the analysis. We identified 12 independent prognostic factors of poor survival: 1) peritoneal metastases; 2) Eastern Cooperative Oncology Group (ECOG) performance score 1; 3) the presence of a primary tumor; 4) time to progression since prior therapy <6 months; 5) poor/unknown tumor differentiation; abnormally low blood levels of 6) albumin, 7) sodium, and/or 8) lymphocytes; and abnormally high blood levels of 9) neutrophils, 10) aspartate aminotransferase (AST), 11) alkaline phosphatase (ALP), and/or 12) lactate dehydrogenase (LDH). Factors were used to devise a 4-tier prognostic index (median overall survival [OS] by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5; Harrell's C-index=0.66; 95% confidence interval [CI], 0.64–0.68). Addition of QoL to the model identified patient-reported appetite loss as an independent prognostic factor. CONCLUSIONS: The identified prognostic factors and the reported prognostic index may help clinical decision-making, patient stratification, and planning of future clinical studies.
Adenocarcinoma
;
Alkaline Phosphatase
;
Appetite
;
Aspartate Aminotransferases
;
Clinical Decision-Making
;
Disease Progression
;
Double-Blind Method
;
Drug Therapy
;
Esophagogastric Junction
;
Factor Analysis, Statistical*
;
Humans
;
L-Lactate Dehydrogenase
;
Lymphocytes
;
Mass Screening
;
Neoplasm Metastasis
;
Neutrophils
;
Prognosis
;
Proportional Hazards Models
;
Quality of Life
;
Sodium
;
Stomach Neoplasms*